Cancer Talk

BRCA Mutation illustration
Article

What is the Difference Between BRCA1 and BRCA2?

BRCA1 and BRCA2 are tumor suppressor genes, meaning when they function normally their job is to keep tumors from forming. Some people however, have an altered or mutated copy of the gene and certain mutations are associated with an increased risk for several cancer types, including breast, ovarian, prostate, pancreatic, melanoma, and in some families, colorectal.
Cancer Support
News

Roswell Park Deputy Director Picked as Board Member for Influential Immunotherapy Organization

Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named an At-Large Director for the Society for Immunotherapy of Cancer (SITC) Board of Directors. The nonprofit organization’s members voted for Dr. Odunsi during their election in May. He will begin his three-year term in January 2021.
Lymphoma on the skin
Article

Can Lymphoma Develop on the Skin?

Your skin can be the site of a type of cancer called cutaneous T-cell lymphoma (CTCL), which can look like eczema or psoriasis, causing scaly or itchy lesions and plaques that cause irritation.
Cancer Support
Remembering Dr. Oscar Colegio
News

Roswell Park Community Mourns Loss of Oscar Colegio, MD, PhD

Roswell Park Comprehensive Cancer Center staff and patients are mourning a devastating loss. Oscar Colegio, MD, PhD, the Lawrence P. & Joan Castellani Family Endowed Chair in Dermatology at the Buffalo-based cancer center, died unexpectedly this weekend at a family residence in Connecticut.
Small intestine cells showing signs of GVHD
News

Roswell Park Suggests New Strategy for Controlling Graft vs. Host Disease in Blood/Marrow Transplant Recipients

New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center’s Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood/marrow transplant (BMT) — a potentially curative treatment for selected patients with hematologic disorders — can be decreased using an existing class of drugs called beta adrenergic agonists.